Haematologic Technologies Revenue and Competitors
Estimated Revenue & Valuation
- Haematologic Technologies's estimated annual revenue is currently $7.8M per year.
- Haematologic Technologies's estimated revenue per employee is $155,000
- Haematologic Technologies has 50 Employees.
- Haematologic Technologies grew their employee count by 0% last year.
Haematologic Technologies Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Haematologic Technologies?
Haematologic Technologies (HTI) is the leading provider of reagents for coagulation research and analytical services to support the research, development and commercialization of large molecule biotherapeutics. HTI has deep expertise in protein biochemistry including characterization of plasma proteins and other large molecules, and performs highly advanced assay development and GMP testing in the areas of immunoassays, thrombin generation assays, assessment of hemostatic risk, anti-drug antibody testing (immunogenity), host cell protein mitigation, stability and release testing, as well as a variety of other specialized assays for biotherapeutics supporting discovery through commercial release. The company's biopharma services are performed in fully compliant, FDA-inspected GMP facilities. Building on its 30+ years of expertise in plasma proteins, hemostasis and blood coagulation, HTI is also a leading global supplier of coagulation research reagents (plasma proteins and antibodies), custom formulated IVD/POC device reagents, as well as customized blood collection tubes to support clinical trials. Visit us at www.haemtech.com.keywords:N/A
Number of Employees
Employee Growth %
Haematologic Technologies News
Vermont Business Magazine Haematologic Technologies, a global analytical and bioanalytical leader for large molecule drug development based...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|